183 related articles for article (PubMed ID: 35025620)
1. Circulating T-Cell Repertoires Correlate With the Tumor Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy.
Cai G; Guan Z; Jin Y; Su Z; Chen X; Liu Q; Wang C; Yin X; Zhang L; Ye G; Luo W
JCO Precis Oncol; 2022 Jan; 6():e2100120. PubMed ID: 35025620
[TBL] [Abstract][Full Text] [Related]
2. Circulating CD8
Lin KR; Pang DM; Jin YB; Hu Q; Pan YM; Cui JH; Chen XP; Lin YX; Mao XF; Duan HB; Luo W
Cancer Immunol Immunother; 2018 Nov; 67(11):1743-1752. PubMed ID: 30167861
[TBL] [Abstract][Full Text] [Related]
3. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy.
Park JH; Jang M; Tarhan YE; Katagiri T; Sasa M; Miyoshi Y; Kalari KR; Suman VJ; Weinshilboum R; Wang L; Boughey JC; Goetz MP; Nakamura Y
Int J Oncol; 2016 Aug; 49(2):471-8. PubMed ID: 27278091
[TBL] [Abstract][Full Text] [Related]
4. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient.
Bernal-Estévez D; Sánchez R; Tejada RE; Parra-López C
BMC Cancer; 2016 Aug; 16():591. PubMed ID: 27484900
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal High-Throughput Sequencing of the T-Cell Receptor Repertoire Reveals Dynamic Change and Prognostic Significance of Peripheral Blood TCR Diversity in Metastatic Colorectal Cancer During Chemotherapy.
Chen YT; Hsu HC; Lee YS; Liu H; Tan BC; Chin CY; Chang IY; Yang CY
Front Immunol; 2021; 12():743448. PubMed ID: 35095836
[TBL] [Abstract][Full Text] [Related]
7. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
[TBL] [Abstract][Full Text] [Related]
8. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
[TBL] [Abstract][Full Text] [Related]
9. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
11. TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer.
Liang H; Huang J; Ao X; Guo W; Chen Y; Lu D; Lv Z; Tan X; He W; Jiang M; Xia H; Zhan Y; Guo W; Ye Z; Jiao L; Ma J; Wang C; Li H; Zhang X; Huang J
Front Oncol; 2021; 11():740427. PubMed ID: 34950580
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
14. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
Hamy AS; Pierga JY; Sabaila A; Laas E; Bonsang-Kitzis H; Laurent C; Vincent-Salomon A; Cottu P; Lerebours F; Rouzier R; Lae M; Reyal F
Ann Oncol; 2017 Sep; 28(9):2233-2240. PubMed ID: 28911063
[TBL] [Abstract][Full Text] [Related]
15. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Imai A; Okamoto A; Hamaoka A; Soushi M; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Goto M; Yamada K; Taguchi T
Breast Cancer; 2017 Jan; 24(1):92-97. PubMed ID: 26874836
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer.
Liu YY; Yang QF; Yang JS; Cao RB; Liang JY; Liu YT; Zeng YL; Chen S; Xia XF; Zhang K; Liu L
Int J Cancer; 2019 Sep; 145(5):1423-1431. PubMed ID: 30664810
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
20. TCR Repertoire as a Novel Indicator for Immune Monitoring and Prognosis Assessment of Patients With Cervical Cancer.
Cui JH; Lin KR; Yuan SH; Jin YB; Chen XP; Su XK; Jiang J; Pan YM; Mao SL; Mao XF; Luo W
Front Immunol; 2018; 9():2729. PubMed ID: 30524447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]